Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) (AIM:POLB, OTCQB:POLBF) has been granted US patents protecting two key assets – POLB 001, a potential flu treatment, and POLB 002, a nasal spray for virus infections.
Jeremy Skillington says the firm is working with its advisors to broaden and expand the patent families for both early-stage drug candidates.
He says the additional US patent protection of POLB 001 and POLB 002 is an important step in the commercialisation of these novel infectious disease products'.